Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.60 |
| ▸ | ULK1 | O75385 | 7/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19654262 | 0.88 | BRD4 (0.74) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL17915936 | 0.85 | BRD4 (0.65) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL19654308 | 0.83 | ULK1 (0.76) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL19654310 | 0.83 | ULK1 (0.76) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL270175 | 0.82 | BRD4 (0.61) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL301350 | 0.82 | BRD4 (0.61) | BRD4ULK1STK17ASTK17BJUN | |
| SCHEMBL19654328 | 0.82 | ULK1 (0.68) | BRD4ULK1STK17ANPC1ALOX15 | |
| SCHEMBL12279025 | 0.81 | BRD4 (0.59) | BRD4ULK1STK17ANPC1ALOX15 | |
| SCHEMBL656136 | 0.80 | BRD4 (0.74) | BRD4ULK1STK17ASTK17BAURKA | |
| SCHEMBL19654299 | 0.80 | BRD4 (0.67) | BRD4ULK1STK17ACDK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | BRD4 1036/4885ULK1 3364/4885STK17A 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.